Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Amur Minerals ( (GB:CRTX) ) has provided an announcement.
CRISM Therapeutics Corporation announced the successful closure of its Retail Offer, raising £59,610 through the sale of 662,332 shares. The funds will support the progression of a Phase 2 clinical trial for irinotecan-ChemoSeed in glioblastoma patients, with dosing expected to begin in Q1 2026. The new shares will be admitted to the London Stock Exchange, increasing the company’s total voting rights to 51,735,266.
More about Amur Minerals
CRISM Therapeutics Corporation specializes in innovative drug delivery technology aimed at enhancing the clinical performance of cancer treatments for solid tumors. Their lead product, ChemoSeed, is designed for direct implantation into tumors or resection margins, allowing chemotherapy drugs to effectively reach deep-seated tumor tissues. This technology is particularly beneficial in treating glioblastoma, as it bypasses the blood-brain barrier.
Average Trading Volume: 73,393
Technical Sentiment Signal: Sell
Current Market Cap: £3.5M
See more insights into CRTX stock on TipRanks’ Stock Analysis page.